CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 45 enrolled
Drug / intervention
CBD 400 mg +2 moredrug
Likely dose
CBD 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02539823
NCT02539823Phase 2Completed
CompareCT.gov

To Characterize the Acute and Short-term Effects of Cannabidiol (CBD) Administration on Cue-induced Craving in Drug-abstinent Heroin-dependent Humans

Hurd,Yasmin, Ph.D.·interventional·Posted Sep 3, 2015·Updated Sep 1, 2022

In Brief

A Phase 2 clinical trial evaluating CBD 400 mg, CBD 800 mg, and 1 other intervention for Opiate Addiction. Completed, enrolled 45 participants across 1 site.

Detailed Summary

Despite the current available therapies for opioid-dependent patients, most patients relapse. This research project focuses on the development of a novel compound, cannabidiol, to modulate opioid craving in humans based on animal models showing its selective effectiveness to inhibit drug-seeking behavior. The development of a targeted treatment for opioid relapse would be of tremendous medical and public health value.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpiate Addiction
CountriesUnited States
CollaboratorsJazz Pharmaceuticals

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 3, 2015
Enrollment StartSep 1, 2015
Primary CompletionMay 24, 2017
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 10.8 years ago

Interventions

CBD 400 mgdrug

Subjects in Arm CBD 400 mg will receive 400mg of Cannabidiol in each of the three test sessions

CBD 800 mgdrug

Subjects in Arm CBD 800 mg will receive 800mg of Cannabidiol in each of the three test sessions

Control (placebo)drug

Subjects will receive a harmless, inactive solution to compare and validate the results of the other arms of the study